Clinical trials
Phase 3 trials in Ecuador
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 5 |
| 2007 | 6 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 3 |
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 3 |
| 2021 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 34 |
| Unknown status | 5 |
| Terminated | 4 |
| Recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 11 |
| Sanofi | 4 |
| Novartis Pharmaceuticals | 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Novartis | 2 |
| Population Health Research Institute | 2 |
| Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 1 |
| Antisoma Research | 1 |
| Athenex, Inc. | 1 |
| Bayer | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 7 |
| Arthritis, Rheumatoid | 5 |
| Anemia | 3 |
| Essential Hypertension | 3 |
| Hypertension | 3 |
| Stroke | 3 |
| Lymphoma, Non-Hodgkin | 2 |
| Myocardial Infarction | 2 |
| Peripheral Arterial Disease | 2 |
| Acute Coronary Syndrome | 1 |
Trials
Showing 51 to 45 of 45. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.